Rob Missere
Rob Missere is the Managing Director of OMERS Private Capital, where he oversees the life sciences investment arm. He recently commented on the financing provided by OMERS for Zymeworks' acquisition of Theravance Biopharma, noting the strategic structure of the deal in the context of OMERS' active role in pharmaceutical royalty monetization.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Canada | 1 | 6.00 | 0.08% | +0% | 38,005,238 | 31,487 | $1,700,000 | 1,408$ |
| Totals | 1 | 38,005,238 | 31,487 | $1,700,000 | 1,408$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Canada:
Rob Missere, managing director of OMERS Private Capital, provided insights on the structure of the Zymeworks deal.
6